07th week of 2013 patent applcation highlights part 44 |
Patent application number | Title | Published |
20130040826 | METHODS FOR TRAIT MAPPING IN PLANTS - The present invention provides methods for identifying the nucleic acid sequences responsible for phenotypic traits in plants. | 2013-02-14 |
20130040827 | METHOD AND COMPOSITIONS FOR DETECTING AND SEQUENCING NUCLEIC ACIDS - The invention is directed to methods of nucleic acid sequencing that use nanopores to detect and/or measure amounts of compounds, such as products or byproducts of nucleic acid sequencing reactions, and to the determination of a nucleotide sequence using such detection and/or measurement. The detection or measurements may employ products or byproducts having resistive-pulse labels, optical labels, or labels that are capable of generating both optical and resistive-pulse signals. Resistive-pulse labels are molecular labels bound or attached to an analyte which allows detection of the labeled analyte by a change in the electrical properties of a nanopore, such as trans-nanopore resistance. Labels for nanopore detection may also be optical labels, particularly acceptors of acceptor-donor pairs capable of undergoing fluorescent resonance energy transfer (FRET), where the donors are associated with, or label, a nanopore. | 2013-02-14 |
20130040828 | METHOD FOR DETECTING GENE REGION FEATURES BASED ON INTER-ALU POLYMERASE CHAIN REACTION - The present invention provides a method for detecting features of genic region based on inter-Alu polymerase chain reaction using segments of the consensus sequences of Alu element family, especially the AluY subfamily, as the main oligonucleotide primers to amplify genomic DNA, followed by massively-parallel DNA sequencing of the amplicons. The features of genomic regions detected comprise single nucleotide polymorphisms (SNP), point mutations, sequence insertion/deletions (indel) and the level of DNA CpG loci methylation. | 2013-02-14 |
20130040829 | IN VITRO MODEL OF LATENT MYCOBACTERIAL INFECTION - A method of inducing latency in | 2013-02-14 |
20130040830 | Fluid Sample Testing System - A sample testing vessel may include a flexible plastic tube and a self-sealing injection channel. The flexible plastic tube may have a seal defining a first compartment and a second compartment, wherein the seal comprises a pressure gate providing a fluid-tight seal between first and second compartments and opening upon application of a threshold pressure. The injection channel may be normally substantially free of fluid and capable of fluid communication with the tubule. | 2013-02-14 |
20130040831 | Predicting Response to Anti-CD40 Therapy in DLBCL Patients - This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments. | 2013-02-14 |
20130040832 | IDENTIFYING VIRAL CELL TROPISM - The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising:
| 2013-02-14 |
20130040833 | USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES - The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for a disease in a subject. | 2013-02-14 |
20130040834 | SAMPLE PLATE SYSTEMS AND METHODS - A sample plate comprising a sample well is disclosed. The sample well can comprise one or more bead retaining chambers. Also provided herein is a method of using the sample plate and kits comprising the sample plate. | 2013-02-14 |
20130040835 | Genes predictive of anti-TNF response in inflammatory diseases - The present invention provides compositions and their use in predicting anti-tumor necrosis factor therapy response in a patient with an inflammatory disease. | 2013-02-14 |
20130040836 | METHODS FOR ENGINEERING T-CELL RECEPTORS - The present invention provides a method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of the T-cell receptor domain polypeptide and determining the binding of the T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to said epitope. The present invention also covers modified T cell receptor domain polypeptides, their use and libraries containing the modified T cell receptor domain polypeptides. | 2013-02-14 |
20130040837 | APTAMER CELL COMPOSITIONS - A composition includes an isolated cell, wherein a surface of the cell is attached to a nucleic acid that specifically binds to a non-nucleic target. | 2013-02-14 |
20130040838 | METHODS FOR IDENTIFYING THE PRESENCE OF A BICUSPID AORTIC VALVE - The present invention features a method for identifying a subject with a bicuspid aortic valve (BAV) by detecting one or more single nucleotide polymorphisms (SNPs) present in one or more BAV-associated chromosomal regions (e.g., chromosomal regions containing the AXIN1-PDIA2, ENG, BAT2/3, or ZNF385D gene(s)). | 2013-02-14 |
20130040839 | Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery - The invention relates to the discovery and use of novel antigens/autoantigens, polyclonal and monoclonal antibodies/autoantibodies thereto, and in particular methods of using the antigens/autoantigens and antibodies/autoantibodies in the diagnostic, prognostic, staging and therapeutic regimens for the control of colorectal cancer. | 2013-02-14 |
20130040840 | NUCLEIC ACID AMPLIFICATION WITH INTEGRATED MULTIPLEX DETECTION - Compositions and methods of detecting multiple proteins of interest in a sample using arrays are provided herein. | 2013-02-14 |
20130040841 | DIGITAL ASSAYS WITH MULTIPLEXED DETECTION OF TWO OR MORE TARGETS IN THE SAME OPTICAL CHANNEL - System, including methods and apparatus, for performing a digital assay with multiplexed detection of two or more distinct targets in the same optical channel. | 2013-02-14 |
20130040842 | Methods And Compositions For Phototransfer - Methods are described for phototransferring a compound from a first surface to a second surface. Compounds are described with photocleavable linkers. Compounds attached to a first surface through a photocleavable linker are put in proximity (or contact) with a second surface, and then phototransferred to the second surface upon exposure to electromagnetic radiation. Illuminating the compound with radiation photocleaves the compound from the first surface and transfers the compound to the second surface. | 2013-02-14 |
20130040843 | Increasing Multiplex Level by Externalization of Passive Reference in PCR Reactions - Methods for increasing multiplex level by externalization of a passive reference in polymerase chain reactions (PCR) are provided. An exemplary method comprises providing a first mastermix including a passive fluorescence dye in at least a first well of a plate; providing a second mastermix including an active fluorescence dye in at least a second well of the plate; wherein the passive fluorescence dye and the active fluorescence dye emit a same spectrum and an intensity of the spectrum is adapted to be measured; and wherein the first mastermix is devoid of an active fluorescence dye emitting the same spectrum and the second mastermix is devoid of the passive fluorescence dye emitting the same spectrum. Numerous other aspects are provided. | 2013-02-14 |
20130040844 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS - Provided are methods of diagnosis, prognosis, and monitoring of aging using biomarkers that have been discovered to be linked to biological aging process. Methods for increasing neural cell regeneration and cognitive function are also provided. The methods are, at least in part, based on a discovery that altered expression patterns of certain biological markers are associated with biological aging processes. These markers comprise at least Eotaxin/CCL11, 2-microglobulin, MCP-1 and Hap-toglobulin, increased expression of which has been shown to be associated with increase in biological aging process. | 2013-02-14 |
20130040845 | METHOD FOR SCREENING RECEPTORS/LIGANDS INTERACTIONS - Embodiments of the invention herein relate to methods of studying binding interactions between two entities and methods for screening of modulators of such binding interactions, in particular, the protein-protein interaction observed in receptor-ligand interactions. | 2013-02-14 |
20130040846 | Signatures for Kidney Aging - Sets of genes associated with aging in the kidney are identified herein, and methods of assessing the health and longevity of the kidney in a human subject are disclosed. Methods include obtaining a DNA sample from the subject and analyzing the sample for the occurrence of at least one single nucleotide polymorphism (SNP) in at least one gene that is identified herein as correlating with physiological aging of the kidney. Also disclosed are potential drug targets for improving the physiological health and lifespan of the kidney. | 2013-02-14 |
20130040847 | ENHANCED MULTIPLEX FISH - Subject of the present invention is a combination of nucleic acid molecules capable of hybridising with a target nucleic acid sequence. In order to overcome problems with the reproducibility of FISH assays and to decrease assay time, hairpin probes are used in combination with helper probes annealing adjacent to the target site of the hairpin probe. | 2013-02-14 |
20130040848 | Methods and Devices for Detecting Structural Changes in a Molecule Measuring Electrochemical Impedance - The invention relates to a method of detecting a structural change in a molecule, said molecule being attached to a surface, said surface being electrically conductive, wherein the phase of the electrochemical impedance at said surface is monitored, and wherein a change in the phase in the electrochemical impedance at said surface indicates a change in the structure of said molecule. The invention further relates to methods for making arrays having molecules such as, polypeptides attached to electrically conductive surfaces such as electrodes, and to arrays. | 2013-02-14 |
20130040849 | METHOD AND KIT FOR CANCER DIAGNOSIS - A method for diagnosing or providing a prognosis of a subject suspected of suffering from prostate cancer, comprising in vitro detection of prostasomes and quantification of prostasomal expression of at least one antigen chosen from the group consisting of CD13, CD59, CD10, CD26 CD142, CD143 and MHC I, and comparing said quantified expression value with a reference value for the respective antigen derived from healthy subject(s). Quotients between said antigens may moreover be made use of. Detection may be by way of flow cytometry or ELISA. A kit for use in diagnosis or providing a prognosis of a subject suspected of suffering from prostate cancer is furthermore provided. | 2013-02-14 |
20130040850 | SEROLOGY ASSAYS - The invention provides methods and kits for measuring the ability of a test sample to inhibit the binding of a receptor expressed by a pathogen to a host cell ligand of the pathogen. | 2013-02-14 |
20130040851 | Evaluation Method for Arteriosclerosis - Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b). | 2013-02-14 |
20130040852 | BIOMARKERS BASED ON A MULTI-CANCER INVASION-ASSOCIATED MECHANISM - The present invention relates to biomarkers which constitute a metastasis associated fibroblast (“MAF”) signature and their use in diagnosing and staging a variety of cancers. It is based, at least in part, on the discovery that identifying the differential expression of certain genes indicates a diagnosis and/or stage of a variety of cancers with a high degree of specificity. In particular, the presence of the signature implies that the cancer has already become invasive. Accordingly, in various embodiments, the present invention provides for methods of diagnosis, diagnostic kits, as well as methods of treatment that include an assessment of biomarker status in a subject. Further, because the differential expression of certain genes can function as marker for the acquisition of metastatic potential, such expression profiles can be used to predict the appropriateness of certain therapeutic interventions, such as the appropriateness of neoadjuvant therapies. Such profiles can also be used to screen for therapeutics capable of inhibiting acquisition of metastatic potential. Accordingly, in various embodiments, the present invention provides for methods of screening therapeutics for their anti-metastatic properties as well as screening kits. | 2013-02-14 |
20130040853 | Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation - The present invention relates to a context-specific forward genetic screen designed to systematically assign relative weight of biological evidence to a library of high-probability driver genetic elements in a genetically defined cancer-sensitized model system whose constellation of engineered mutations reflects a particular clinically relevant genetic subclass of a given tumor type. The screen may be formed in vivo or ex vivo. The screen allows for the formulation of clinical path hypotheses for targeting driver genetic elements and, in parallel, the rapid functional validation of the role of the driver genetic element(s) in the cancer. In this manner, the context-specific genetic screen can systematically assign the biological relevance of a library of genetic elements to a clinically-definable genetic and disease context, as well as inform combinations of drugs in the clinic such one uses one drug that targets the newly discovered genetic element or its protein and another drug that targets those genetic elements or its associated proteins which have been engineered into the primary cell model. | 2013-02-14 |
20130040854 | DEVELOPMENT OF A HIGH-THROUGHPUT SCREEN FOR THE IDENTIFICATION OF NOVEL ANTIFUNGAL DRUG CANDIDATES - In one embodiment, a testing device includes a substrate and a plurality of spatially distinct fungal cultures disposed on the substrate. | 2013-02-14 |
20130040855 | HANGING DROP DEVICES, SYSTEMS AND/OR METHODS - The present disclosure relates general to devices, systems, and methods of using such devices in creating and handling hanging drops of fluid. The present disclosure also relates to cell culture devices, methods and/or systems of using such devices as well as the use of cell culture devices, for example, for research and high throughput screening. | 2013-02-14 |
20130040856 | Generation of Combinatorial Patterns by Deliberate Tilting of a Polymer-Pen Array - The disclosure relates to a method of forming a pattern having pattern elements with a plurality of sizes on a substrate surface with a tilted pen array that includes choosing a tilt geometry for a pen array with respect to a substrate, inducing the tilt geometry between the pen array and the substrate surface, and forming a pattern having pattern elements on the substrate surface with the titled pen array, whereby the size of the formed pattern elements varies across the substrate surface along the tilted axis or axes. For example, the tilt geometry is in reference to the substrate surface and comprises a first angle with respect to a first axis of the substrate and a second angle with respect to a second axis of the substrate, the second axis being perpendicular to the first axis, and at least one of the first and second angles being non-zero. | 2013-02-14 |
20130040857 | MASS SPECTROMETRIC ASSAYS FOR PEPTIDES - Methods for interpretation of mass spectrometric tests for clinical biomarkers in which the amounts of internal standards are set to equal clinical evaluation thresholds, and preparations for adding stable isotope labeled peptide species to sample digests while minimizing losses and alterations in peptide stoichiometry. | 2013-02-14 |
20130040858 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 2013-02-14 |
20130040859 | SPECTRALLY-RESOLVED CHEMILUMINESCENT PROBES FOR SENSITIVE MULTIPLEX MOLECULAR QUANTIFICATION - Hybrid luminescent probes emit light of distinct wavelength ranges and intensities upon energy transfer from an in-common, acridinium ester chemiluminophore to a coupled luminophore. The probes include: (1) a target binding region with a base sequence that is substantially complementary to a portion of the target nucleic acid sequence; (2) an acridinium ester (AE) moiety attached to a first region flanking the target binding region; (3) a luminophore coupled to the AE moiety to allow energy transfer from an acridone moiety, produced by a chemical triggering of the AE moiety, to the luminophore; and (4) a quencher moiety attached to a second region flanking the target binding region, such that the first and second flanking regions are on the opposite sides of the target binding region. The probes are particularly useful in homogeneous assays for sensitive, multiplex quantification of nucleic acid target sequences without prior enzymatic amplification. | 2013-02-14 |
20130040860 | MICROARRAY SYSTEM WITH IMPROVED SEQUENCE SPECIFICITY - The invention provides a novel array method for nucleic acid sequence detection with improved specificity which allows for detection of genetic variation, from simple SNPs (where the variation occurs at a fixed position and is of limited allelic number) to more complex sequence variation patterns (such as with multigene families or multiple genetic strains of an organism where the sequence variation between the individual members is neither fixed nor consistent). The array is comprised of short, synthetic oligonucleotide probes attached to a solid surface which are hybridized to single-stranded targets. Single stranded targets can be produced using a method that employs primers modified on the 5′ end to prohibit degradation by a 5′-exonuclease that is introduced to degrade the unprotected strand. The invention further provides for printing buffers/solutions for the immobilization of oligonucleotide probes to an array surface. The invention also provides hybridization and wash buffers and conditions to maximize hybridization specificity and signal intensity, and reduce hybridization times. | 2013-02-14 |
20130040861 | NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES - Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed. | 2013-02-14 |
20130040862 | MULTI-PILLAR STRUCTURE FOR MOLECULAR ANALYSIS - A multi-pillar structure for molecular analysis is provided. The structure comprises at least two nanopoles, each nanopole attached at one end to a substrate and freely movable along its length. The opposite ends of the at least two nanopoles are each capable of movement toward each other to trap at least one analyte molecule at their opposite ends. Each nanopole is coated with a metal coating. An array of such multi-pillar structures is also provided. A method for preparing the multi-pillar structure is further provided. | 2013-02-14 |
20130040863 | SOLID-PHASE CLONAL AMPLIFICATION AND RELATED METHODS - The present invention provides methods and compositions for analyzing nucleic acid sequences. In some aspects, the methods utilize clonal objects, such as DNA balls, that have been captured on beads. Using the methods described here, compositions are fabricated wherein a bead and one clonal object are affinity bound or hybridized to each other through an affinity binding patch or hybridization patch on the surface of the bead. The invention also provides a population of beads having affinity bound or hybridized clonal objects at a ratio of 1:1. The invention additionally provides methods for amplifying a target nucleic acid molecule utilizing the compositions described herein. | 2013-02-14 |
20130040864 | Microgels combined with functional additives - The invention relates to a composition comprising at least one microgel and at least one functional additive, to processes for the preparation thereof, to uses of the compositions, and to microgel-containing polymers, rubbers, lubricants, coatings, etc. prepared therefrom. | 2013-02-14 |
20130040865 | SUCCINIMIDE COMPOUND, LUBRICATING OIL ADDITIVE, AND LUBRICATING OIL COMPOSITION - The present invention provides a succinimide compound represented by the following formula (1-1) or (1-2), and a lubricating oil additive and a lubricating oil composition which contain the succinimide compound. | 2013-02-14 |
20130040866 | LUBRICANT COMPOSITIONS CONTAINING A FUNCTIONALIZED DISPERSANT - An engine lubricant composition, a method for maintaining the soot or sludge handling capability of an engine lubricant while not adversely affecting elastomeric seal material in the engine and a method of operating an engine. The engine lubricant includes a base oil and a dispersant. The dispersant is a reaction product of A) a hydrocarbyl-dicarboxylic acid or anhydride, B) a polyamine, C) a dicarboxyl-containing fused aromatic compound, and D) a non-aromatic dicarboxylic acid or anhydride. | 2013-02-14 |
20130040867 | TRUNK PISTON ENGINE LUBRICATING OIL COMPOSITIONS - A trunk piston engine lubricating oil composition is disclosed comprising (a) a major amount of a base stock containing at least 90% by weight saturated hydrocarbons; and (b) a base stock selected from the group consisting of (i) an ester base stock wherein the ester base stock is present in an amount greater than 10% by weight and no greater than about 45% by weight, based on the total weight of the lubricating oil composition, and (ii) an alkylated aromatic base stock. | 2013-02-14 |
20130040868 | RESIN COMPOSITION WHOSE LUBRICITY UNDER WET CONDITIONS IS MAINTAINED - Provided is a resin composition which has excellent lubricity and a good touch feeling under wet conditions and suffers from little deterioration in the lubricity or the good touch feeling even if used repeatedly, and is excellent in flexibility. More specifically, the resin composition contains 100 parts by mass of a water-absorbing polymer and 60 to 500 parts by mass of a thermoplastic resin that has a type D durometer hardness (HDD) of 10 to 60. | 2013-02-14 |
20130040869 | MILD TO THE SKIN, FOAMING DETERGENT COMPOSITION - A mild to the skin, foaming detergent composition comprising: a) 1 to 20 wt % sophorolipid biosurfactant, b) 1 to 20 wt % of anionic surfactant selected from the group consisting of glycinate, sulphosuccinate, and mixtures thereof, c) 0 to 10 wt % foam boosting surfactant, d) 0 to 2 wt % additional electrolyte, e) 0 to 10 wt % additional additives, f) 40 to 98 wt % water. The anionic surfactant is preferably disodium laureth-3-sulphosuccinate. The electrolyte may be sodium chloride, the foam boosting surfactant may be olivamidopropyl betaine and the additional additives may be silicones, polymers, structurants, thickeners or pH adjusters. A preferred additive is a dispersed modified cellulose biopolymer as structurant. The composition is suitable for personal wash, shower gel and shampoo formulations. | 2013-02-14 |
20130040870 | USE OF A COPOLYMER AS THICKENER IN LIQUID DETERGENTS HAVING LOWER GRAYING TENDENCY - The invention relates to copolymers which contain a) at least 15% by weight units of an ethylenically unsaturated carboxylic acid, b) at least 15% by weight units of a C | 2013-02-14 |
20130040871 | ANTIFOAM COMPOSITIONS - Superior defoamer compositions contain a low viscosity linear organopolysiloxane, a higher viscosity, optionally branched organopolysiloxane, a polyethersiloxane with a low cloud point, and both colloidal silica and fumed silica. | 2013-02-14 |
20130040872 | ENZYME GRANULES - The stability of enzymes in a powder detergent can be very significantly improved by the combination of four measures: Addition of reducing agent/peroxide decomposing catalyst/antioxidant to the core or the coating; Addition of a multivalent cation to the core; Addition of an acidic buffer to the core or to the coating; Applying a salt coating onto the core. | 2013-02-14 |
20130040873 | QUATERNARY FUNCTIONALIZED ALKYL POLYGLUCOSIDES FOR ENHANCED FOOD SOIL REMOVAL - A cleaning composition including a primarily C | 2013-02-14 |
20130040874 | Branched Hydroxyalkyl Polyoxylene Glycol Ethers - Certain branched hydroxyalkyl polyoxylene glycol ethers exhibit excellent characteristics as defoamers or foam-suppressing additives or as foam regulators for aqueous media that contain foaming agents, even at temperatures of 25° C. and below. Therefore, said branched hydroxyalkyl polyoxylene glycol ethers can be used in detergents and cleaning agents. | 2013-02-14 |
20130040875 | PROCESS FOR PRODUCING POLYSILOXANES WITH NITROGEN-CONTAINING GROUPS - A process for producing amino-functional polysiloxanes by reacting the components A) identical or different terminally hydroxy-functional, linear or branched polysiloxanes, B) identical or different alkoxysilanes of the formula | 2013-02-14 |
20130040876 | METHOD FOR SENSITIZING CELLS TO CANCER THERAPY - Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth hormone and placental lactogen, or one or more of human prolactin, growth hormone and placental lactogen in conjunction with a cytotoxic agent. In some embodiments, the cytotoxic agent comprises a chemotherapeutic agent. | 2013-02-14 |
20130040877 | LONG-ACTING Y2 RECEPTOR AGONISTS - The present invention relates to PYY analogues or derivatives thereof comprising at least one alteration selected from the group consisting of substitutions, insertions, deletions and modifications and optionally a serum albumin binding side chain comprising an alkyl chain with at least 14 carbon atoms. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y2 receptor modulation. | 2013-02-14 |
20130040878 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF DIABETES TYPE 2 PATIENTS - The present invention refers to a pharmaceutical combination for use in the treatment of diabetes type 2 patients. | 2013-02-14 |
20130040879 | Methods For Treating Congestive Heart Failure - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 2013-02-14 |
20130040880 | Novel Cytokine Containing Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 2013-02-14 |
20130040881 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria. | 2013-02-14 |
20130040882 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS - A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants. | 2013-02-14 |
20130040883 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation. | 2013-02-14 |
20130040884 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG - Novel polypeptide derivatives having protracted profile of action. | 2013-02-14 |
20130040885 | COLLAGEN PAD - The present invention relates to a collagen pad and to processes for the manufacture thereof. One aspect of the invention provides a process for the manufacture of a collagen pad from a plurality of collagen particles, said process comprising steps of forming a dispersion of the collagen particles in an aqueous acid solution; and adding a flocculating agent to the dispersion to form a collagen floe. A further aspect of the invention provides a process for the manufacture of a collagen pad, wherein said process comprises a step of centrifuging the product of a flocculation reaction, said flocculation reaction comprising adding a flocculating agent to a dispersion of collagen particles in an aqueous acid solution to form a collagen floe. The collagen pad may be used, for example, in wound care. | 2013-02-14 |
20130040886 | Peptides and Methods for Inhibiting G alpha Protein Signaling - The present invention comprises peptide compositions and methods for specifically inhibiting signaling through Gα subunits. | 2013-02-14 |
20130040887 | Inhibiting Collagen-Induced Platelet Aggregation and Activation with Peptide Variants - The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents). | 2013-02-14 |
20130040888 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 2013-02-14 |
20130040889 | Factor VIII Fusion Protein - The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain. | 2013-02-14 |
20130040890 | LYOPHILIZATION METHODS, COMPOSITIONS, AND KITS - Method for lyophilization is provided, in particular methods for lyophilization of formulations comprising AT III. Also provided are compositions prepared by therefrom. Also provided are kits comprising the compositions and/or lyophilized products. | 2013-02-14 |
20130040891 | CHEMICALLY MODIFIED WATER-SOLUBLE ELASTIN, MIXED GEL OF CHEMICALLY MODIFIED WATER-SOLUBLE ELASTIN AND COLLAGEN, AND PROCESS FOR PRODUCING SAME - A chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or all of the carboxyl groups contained in the molecule with the amino group of an amino acid alkyl ester. | 2013-02-14 |
20130040892 | IAP BIR DOMAIN BINDING COMPOUNDS - A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods. | 2013-02-14 |
20130040893 | TREATMENT OF PROLIFERATIVE DISORDERS - Inhibitors of cIAP-1 and methods and compositions for treating proliferative disorders. | 2013-02-14 |
20130040894 | INHIBITION OR ACTIVATION OF SERINE/THREONINE ULK3 KINASE ACTIVITY - The present invention relates to human serine/threonine kinase ULK3 and its ability to regulate GLI transcription factors; mediators of SHH signaling. This disclosure demonstrates that ULK3 enhances endogenous and over-expressed GLI1 and GLI2 transcriptional activity in cultured cells, and ULK3 alters subcellular localization of GLI1. According to this disclosure ULK3 is an autophosphorylated kinase and phosphorylates GLI proteins in vitro. A peptide sequence in GLI1 C-terminus that is phosphorylated by ULK3 is provided in this disclosure. ULK3 catalytical activity is shown to be crucial for its function in SHH pathway. This disclosure shows that serine/threonine kinase ULK3 is involved in the SHH pathway as a positive regulator of GLI proteins. Furthermore, a therapeutic method in SHH dependent human disorders is disclosed by pharmacological inhibition of ULK3 kinase activity. Identification of ULK3 substrate sequence in GLI1 allows the design of peptide-based modulators of its kinase activity. | 2013-02-14 |
20130040895 | Pharmaceutical Formulations and Methods for Treating Ocular Conditions - Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit. | 2013-02-14 |
20130040896 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 2013-02-14 |
20130040897 | GLYCOSYLATION OF PROTEINS IN HOST CELLS - The invention provides means and methods for an improved production of glycosylated recombinant proteins in lower eukaryotes, specifically the production of human-like complex or hybrid glycosylated proteins in yeast. The invention provides genetically modified eukaryotic host cells capable of producing glycosylation optimized proteins useful as immunoglobulins and other therapeutic proteins, and provides cells capable of producing glycoproteins having glycan structures similar to glycoproteins produced in human cell. The invention further provides proteins with human-like glycan structures and novel compositions thereof producible by these modified cells. | 2013-02-14 |
20130040898 | METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF - The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and/or no-reflow phenomena and/or ischemia-reperfusion injury by administration of agent(s) modulating and/or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb/IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents. | 2013-02-14 |
20130040899 | Use of PEDF-Derived Polypeptides for Treating Liver Cirrhosis - The present disclosure elucidates that 34-mer PEDF suppresses hepatic stellate cells (HSCs) from activation by diminishing the levels of alpha-smooth muscle actin (α-SMC), collagen type 1, and monocyte chemoattractant protein-1 (MCP-1); and 44-mer PEDF promotes liver regeneration process by enhancing the replication of liver-derived progenitor cells (LDPCs). Accordingly, methods and compositions directing to the new use of the 34-mer PEDF or 44-mer PEDF in patients suffering from liver cirrhosis are provided herein. | 2013-02-14 |
20130040900 | PEPTIDES EFFECTIVE IN THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS - The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein. | 2013-02-14 |
20130040901 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY - The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide. | 2013-02-14 |
20130040902 | METHOD FOR ENHANCING MILK QUANTITY AND QUALITY - This invention provides a method for enhancing quantity and quality of milk in mammals, while improving their health. The method particularly enables to substantially increase global milk production and improve economy of the dairy industry, without negatively affecting the wellbeing of dairy cattle. | 2013-02-14 |
20130040903 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DEPRESSION AND ANXIETY - Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rgl+Rbl), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy. | 2013-02-14 |
20130040904 | METHOD OF TREATMENT USING ALPHA-1-ADRENERGIC AGONIST COMPOUNDS - Methods for treating or preventing cardiomyopathy in a subject by administering an α1 adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided. | 2013-02-14 |
20130040905 | Combination Of Drugs With Protein-Binding Prodrugs - The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination. | 2013-02-14 |
20130040906 | Inhibitors of Human EZH2, and Methods of Use Thereof - The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject. | 2013-02-14 |
20130040907 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2013-02-14 |
20130040908 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS - Substitution derivatives of N | 2013-02-14 |
20130040909 | COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2013-02-14 |
20130040910 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - A novel method and composition for treating vitamin B | 2013-02-14 |
20130040911 | ADHESION-PREVENTING MATERIAL - Provided are a novel carboxymethyl cellulose (CMC) structure and a method for producing the same. The CMC structure of the present invention is useful as a medical material and particularly as an adhesion-preventing material, and has good biocompatibility and bioabsorbability and controllable periods of functioning and dissolving, or has both effects for preventing adhesions and wound healing. | 2013-02-14 |
20130040912 | PIPERAZINOTRIAZINES AS PI3K INHIBITORS FOR USE IN THE TREATMENT ANTIPROLIFERATIVE DISORDERS - The invention relates to compounds of formula (I) R1 is methyl, n-hexyl, aminoethyl, methylaminoethyl, ethylaminoethyl, dimethylaminoethyl, acryloylaminoethyl, methacryloylaminoethyl, methoxyethyl, ethoxyethyl, d-C4-alkyl-sulfonyl, acryloyl, or methacryloyl; or R1 is aminoethyl, acryloyl or acryloylaminoethyl carrying a linker and a tag, and R2 and R3, independently of each other, are hydrogen or CrC4-alkyl, or R2 and R3 together form a methylene or an ethylene bridge; and tautomers, solvates and pharmaceutically acceptable salts thereof. These compounds are effective in preventing or treating a disease or disorder modulated by PI3 kinases and/or mTOR, in particular treating a hyperproliferative disorder. | 2013-02-14 |
20130040913 | OMEGA 3 FATTY ACIDFOR USE AS A PRESCRIPTION MEDICAL FOOD AND OMEGA 3 FATTY ACID DIAGNIOSTIC ASSAY FOR THE DIETARY MANAGEMENT OF CARDIOVASCULAR PATIENTS WITH CARDIOVASCULAR DISEASE (CVD) WHO ARE DEFICIENT IN BLOOD EPA AND DHA LEVELS - The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components. | 2013-02-14 |
20130040914 | PRODRUGS OF AN HIV REVERSE TRANSCRIPTASE INHIBITOR - Compounds of Formula I are described: (I), wherein R | 2013-02-14 |
20130040915 | PHARMACEUTICAL COMPOSITION - An injectable pharmaceutical composition contained in a receptacle for injection into a human, which comprises a solution of zoledronic acid or the salts thereof, a solvent and a pH regulator. | 2013-02-14 |
20130040916 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 2013-02-14 |
20130040917 | Phenazopyridine Compounds - The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine. | 2013-02-14 |
20130040918 | TETRACYCLINE COMPOSITIONS - The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation. | 2013-02-14 |
20130040919 | C-NITROSO-DERIVED NITROXYL DONORS - Active compounds of Formula I are described: | 2013-02-14 |
20130040920 | COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL - The present invention is a method for obtaining a formulation of resveratrol and rice bran oil. The resulting product in the form of an oil or solid proves to increase the therapeutic potential of resveratrol by the synergistic action of the components of the rice oil. | 2013-02-14 |
20130040921 | ANTICANCER STEROIDAL LACTONES UNSATURATED IN POSITION 7 (8) - A compound of general formula (I), wherein R | 2013-02-14 |
20130040924 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents. | 2013-02-14 |
20130040925 | OSMIUM (II) ARENE AZO ANTI-CANCER COMPLEXES - The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes. | 2013-02-14 |
20130040926 | NOVEL COMPOUND - There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. | 2013-02-14 |
20130040927 | CHOLESTEROL ABSORPTION INHIBITOR AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF CHOLESTEROL AND FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR, CARDIAC AND VASCULAR EVENTS - A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. | 2013-02-14 |